Piwowarska Jadwiga, Dryll Karolina, Szelenberger Waldemar, Pachecka Jan
Department of Biochemistry and Clinical Chemistry, Medical University, Warsaw, Poland.
Acta Pol Pharm. 2008 Jan-Feb;65(1):159-64.
The aim of this research was to find out whether increased plasma cortisol levels appear in unipolar or bipolar patients with major depressive disorder (MDD) and whether the effective antidepressant treatment by imipramine and fluoxetine leads to regulation of the cortisol level. Cortisol levels were studied in two groups of patients with major depressive disorder: unipolar and bipolar patients treated with fluoxetine (doses: 20-60 mg/day). This group included 5 patients (age 29-46 yr); unipolar and bipolar subjects treated with imipramine (50-150 mg/day), this group included 5 patients (aged 24-70 yr). Cortisol and fluoxetine or imipramine plasma levels were assessed using HPLC methods: before treatment, after 3, 6 and 24 h of drug administration as well as in the 2nd, 4th, 6th, and 8th week of antidepressant treatment. HPLC methods were previously validated. The research conducted and the clinical data may be useful for proving the essential role of enhanced HPA axis activity for the pathogenesis and depressive disorder proceedings.
本研究的目的是探究单相或双相重度抑郁症(MDD)患者的血浆皮质醇水平是否升高,以及丙咪嗪和氟西汀的有效抗抑郁治疗是否会导致皮质醇水平的调节。对两组重度抑郁症患者的皮质醇水平进行了研究:接受氟西汀治疗的单相和双相患者(剂量:20 - 60毫克/天)。该组包括5名患者(年龄29 - 46岁);接受丙咪嗪治疗的单相和双相受试者(50 - 150毫克/天),该组包括5名患者(年龄24 - 70岁)。使用HPLC方法评估皮质醇以及氟西汀或丙咪嗪的血浆水平:治疗前、给药3、6和24小时后以及抗抑郁治疗的第2、4、6和8周。HPLC方法先前已得到验证。所进行的研究和临床数据可能有助于证明增强的HPA轴活性在发病机制和抑郁症病程中的重要作用。